131 related articles for article (PubMed ID: 24637719)
1. BikDDA, a mutant of Bik with longer half-life expression protein, can be a novel therapeutic gene for triple-negative breast cancer.
Jiao S; Wu M; Ye F; Tang H; Xie X; Xie X
PLoS One; 2014; 9(3):e92172. PubMed ID: 24637719
[TBL] [Abstract][Full Text] [Related]
2. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment.
Lang JY; Hsu JL; Meric-Bernstam F; Chang CJ; Wang Q; Bao Y; Yamaguchi H; Xie X; Woodward WA; Yu D; Hortobagyi GN; Hung MC
Cancer Cell; 2011 Sep; 20(3):341-56. PubMed ID: 21907925
[TBL] [Abstract][Full Text] [Related]
3. Targeted expression of BikDD combined with metronomic doxorubicin induces synergistic antitumor effect through Bax activation in hepatocellular carcinoma.
Dai HY; Chen HY; Lai WC; Hung MC; Li LY
Oncotarget; 2015 Sep; 6(27):23807-19. PubMed ID: 26247632
[TBL] [Abstract][Full Text] [Related]
4. Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells.
Okamoto K; Zaanan A; Kawakami H; Huang S; Sinicrope FA
Mol Cancer Res; 2015 Apr; 13(4):659-69. PubMed ID: 25548100
[TBL] [Abstract][Full Text] [Related]
5. Targeted expression of BikDD eliminates breast cancer with virtually no toxicity in noninvasive imaging models.
Xie X; Li L; Xiao X; Guo J; Kong Y; Wu M; Liu W; Gao G; Hsu JL; Wei W; Hung MC; Xie X
Mol Cancer Ther; 2012 Sep; 11(9):1915-24. PubMed ID: 22752427
[TBL] [Abstract][Full Text] [Related]
6. Src tyrosine kinase inhibits apoptosis through the Erk1/2- dependent degradation of the death accelerator Bik.
Lopez J; Hesling C; Prudent J; Popgeorgiev N; Gadet R; Mikaelian I; Rimokh R; Gillet G; Gonzalo P
Cell Death Differ; 2012 Sep; 19(9):1459-69. PubMed ID: 22388352
[TBL] [Abstract][Full Text] [Related]
7. The Utilization of Poly(2-ethyl-2-oxazoline)-b-Poly(ε-caprolactone) Ellipsoidal Particles for Intracellular BIKDDA Delivery to Prostate Cancer.
Kocak P; Oz UC; Bolat ZB; Ozkose UU; Gulyuz S; Tasdelen MA; Yilmaz O; Bozkir A; Sahin F; Telci D
Macromol Biosci; 2021 Feb; 21(2):e2000287. PubMed ID: 33191572
[TBL] [Abstract][Full Text] [Related]
8. Suppression of the death gene BIK is a critical factor for resistance to tamoxifen in MCF-7 breast cancer cells.
Viedma-Rodriguez R; Baiza-Gutman LA; García-Carrancá A; Moreno-Fierros L; Salamanca-Gómez F; Arenas-Aranda D
Int J Oncol; 2013 Dec; 43(6):1777-86. PubMed ID: 24100375
[TBL] [Abstract][Full Text] [Related]
9. Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival.
Sher YP; Tzeng TF; Kan SF; Hsu J; Xie X; Han Z; Lin WC; Li LY; Hung MC
Oncogene; 2009 Sep; 28(37):3286-95. PubMed ID: 19597463
[TBL] [Abstract][Full Text] [Related]
10. BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells.
Das CK; Linder B; Bonn F; Rothweiler F; Dikic I; Michaelis M; Cinatl J; Mandal M; Kögel D
Neoplasia; 2018 Mar; 20(3):263-279. PubMed ID: 29462756
[TBL] [Abstract][Full Text] [Related]
11. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
12. p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy.
Coradini D; Biganzoli E; Ardoino I; Ambrogi F; Boracchi P; Demicheli R; Daidone MG; Moliterni A
Breast; 2015 Jun; 24(3):294-7. PubMed ID: 25698149
[TBL] [Abstract][Full Text] [Related]
13. Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Ho SY; Lin P; Wang YJ
Mol Cancer; 2016 Jun; 15(1):46. PubMed ID: 27286975
[TBL] [Abstract][Full Text] [Related]
14. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
[TBL] [Abstract][Full Text] [Related]
15. The pro-apoptotic paradox: the BH3-only protein Bcl-2 interacting killer (Bik) is prognostic for unfavorable outcomes in breast cancer.
Pandya V; Glubrecht D; Vos L; Hanson J; Damaraju S; Mackey J; Hugh J; Goping IS
Oncotarget; 2016 May; 7(22):33272-85. PubMed ID: 27120789
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation.
Zhu H; Guo W; Zhang L; Wu S; Teraishi F; Davis JJ; Dong F; Fang B
Cancer Biol Ther; 2005 Jul; 4(7):781-6. PubMed ID: 16082182
[TBL] [Abstract][Full Text] [Related]
17. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-455-3p promotes invasion and migration in triple negative breast cancer by targeting tumor suppressor EI24.
Li Z; Meng Q; Pan A; Wu X; Cui J; Wang Y; Li L
Oncotarget; 2017 Mar; 8(12):19455-19466. PubMed ID: 28038450
[TBL] [Abstract][Full Text] [Related]
19. CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers.
Cheriyan VT; Muthu M; Patel K; Sekhar S; Rajeswaran W; Larsen SD; Polin L; Levi E; Singh M; Rishi AK
Oncotarget; 2016 Nov; 7(45):73370-73388. PubMed ID: 27687593
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy enriches for an invasive triple-negative breast tumor cell subpopulation expressing a precursor form of N-cadherin on the cell surface.
Nelson ER; Li S; Kennedy M; Payne S; Kilibarda K; Groth J; Bowie M; Parilla-Castellar E; de Ridder G; Marcom PK; Lyes M; Peterson BL; Cook M; Pizzo SV; McDonnell DP; Bachelder RE
Oncotarget; 2016 Dec; 7(51):84030-84042. PubMed ID: 27768598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
